PFAS webinar DJ van Zoelen

NRDEN^Å

12 December 2024


Navigating you through drug development

• Agenda of the webinar


• PFAS and API's
• PFAS and API synthesis
• PFAS and API manufacturing



PFAS and API's









Enoxacin (1986)

Mefloquine (1986)

Ciprofloxacin (1987)

0

Fluphenazine (1988)

HO




OH 0. HO''

¹⁸F-Fluodeoxyglucose (1994)


Riluzole (1995)

Lansoprazole (1995)




Ъ





Celecoxib (1999)



ö NH₂

Sitagliptin (2006)

HN

ŌΗ $\circ =$ *Oi*Pr

Sofosbuvir (2013)

0



NH₂

Favipiravir (2014)

¹⁸F OH

,OH

 H_2N

OCF₃

CI

Н

F₃C

F₃C

,0

NH

°O

Efavirenz (1998)

) PFAS and API's

 API's containing a CF2, CF3 or multiple fluorine atoms are considered as PFAS

- Since the introduction of the first fluorocorticosteroid, fludrocortisone, in 1954
- with 20% of those on the market being fluorinated drugs and around 30% of fluorinated drugs being blockbuster pharmaceuticals, such as Lipitor, Fluoxetine, Linezolid or Fluticasone
- To date, more than 300 fluorinated pharmaceuticals have been approved for use as drugs

Fluorinated Heterocyclic Drugs from 2016 to 2022. Int. J. Mol. Sci. 2023, 24, 7728

) PFAS and API's

- The success of the introduction of fluorine atoms is linked to the peculiar physicochemical properties of the C-F bond, which are the high bond strength, polarity and minimal steric hindrance of fluorine, combined with a general metabolic stability
- The importance of fluorinated compounds is also linked to their use as diagnostic tools within imaging techniques such as 19F-MRI and 18F-PET

) PFAS and API's \rightarrow Challenge

- For current launched API's derogation conditions are being discussed
- API's under development (clinical trials) are excluded from the derogation conditions
- Rethink your strategy when you are developing a PFAS API
 Other mechanisms should be developed metabolic stability




) PFAS and API Synthesis



> PFAS and API Synthesis

 While launched PFAS API's are not "restricted" yet, PFAS chemicals will be restricted in the near future. But how to make the PFAS API's when PFAS chemicals are restricted?




Wei Zhu, Jiang Wang, Shuni Wang, Zhanni Gu, José Luis Aceña, Kunisuke Izawa, Hong Liu, Vadim A. Soloshonok. Journal of Fluorine Chemistry, Volume 167, November 2014, Pages 37-54

ARDENÅ


> PFAS and API's Synthesis, There is hope!

Integrated flow system

The Science paper presents a versatile microfluidic flow module for generating reactive N–, S– and O–CF₃ anions. These are prepared in a packed bed flow reactor containing the caesium fluoride salt. Appropriate (S, O or N containing) precursors are then led through this reactor.



Laboratory set-up of the microfluidic flow module for generating reactive N–, S– and O–CF3 anions. 1: Solution containing precursor molecules. 2: Packed bed reactor containing the caesium fluoride salt. 3: Nitrogen filled balloon that prevents pressure build-up. 4: Reception vial equipped with stirring bar. Image: HIMS / Science.




ARDFNÅ

Mauro Spennacchio, Miguel Bernús, Jelena Stanić, Daniele Mazzarella, Marco Colella, James J. Douglas, Omar Boutureira, Timothy Noël. Science, 385, 6712, p991-996

PFAS and API Synthesis


 PFAS chemicals will be restricted in the future. But how to make the API's which depend in the route of synthesis on PFAS chemicals? E.g. Peptides?



Peptide Synthesis - Methods and Reagents (antibodies-online.com)

) PFAS and API Synthesis. There is hope!





Brønsted Acid–Lewis Acid (BA–LA) Induced Final Deprotection/Peptide Resin Cleavage in Fmoc/t-Bu Solid-Phase Peptide Synthesis: HCl/FeCl₃ and AcOH/FeCl₃ as Viable PFAS-Free Alternatives for TFA



Jan Pawlas, Christophe André, Jon H. Rasmussen, Olivier Ludemann-Hombourger Org. Lett. 2024, 26, 31, 6787–6791 Essential Medicines List includes Oxytocin for use during pregnancy, childbirth and postpartum care (who.int)

) PFAS and API's Synthesis \rightarrow Challenge

First alternatives for PFAS chemicals have been developed
 Continue this journey \rightarrow Keep developing

- o Start switching to alternatives, already in early development!
- Support each other, share results to the broader public. This challenges is not for a single company; it is for the broader community!



> PFAS and API Manufacturing

ARDEN^Å


> PFAS and API Manufacturing













∧RDENÅ

• PFAS and API's Manufacturing \rightarrow Challenge

H₂N


- These PFAS materials are used in many types of equipment
 Equipment is protected to corrosive conditions
- Used a lot to manufacture non-PFAS API's without using PFAS chemicals

O-CH₃

apixaban

Eliquis (Anticoagulant)

New materials should be developed
We have done it before.....!



Source: GlobalData, Pharma Intelligence Center

Navigating you through drug development

